‘FindDLB’ – A leading platform for Swedish research in Dementia with Lewy Bodies

Dementia with Lewy bodies (DLB) is the second most common form of neurodegenerative dementia, but it is considerably under-diagnosed.

The main reasons for this are the lack of a reliable biomarker for Lewy pathology, and that many DLB patients also have Alzheimer and cerebrovascular pathologies in their brains. ´Find-DLB’ is a leading international platform to tackle these problems.The purpose of ‘Find-DLB’ is to intensify DLB research in Sweden, with a strong focus on novel biomarkers and translation to precision medicine. ‘Find-DLB’ spans from 2023 to 2027, including (1) testing of a novel biomarker of Lewy pathology for immediate clinical use in hospitals across Sweden; (2) development of new imaging biomarkers to disentangle mixed pathologies and (3) elucidate what causes brain degeneration in DLB; (4) development of precision medicine risk profiles and diagnostic tools, with a strong focus on sex differences. ‘Find-DLB’ will create a prospective Swedish cohort and use unique large international data, including around 6000 participants, the largest platform of this kind.‘Find-DLB’ strives to transform the way we diagnose DLB today.

It will improve management and care of our DLB patients, and will increase social awareness about the disease.

Project’s findings will set the ground for precision medicine-based therapies. ‘Find-DLB’ is an unprecedented multicohort platform including collaborations among multiple centers across the world.